ProfileGDS5678 / 1430086_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 69% 73% 65% 69% 73% 75% 69% 69% 69% 70% 63% 70% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3557170
GSM967853U87-EV human glioblastoma xenograft - Control 24.3052369
GSM967854U87-EV human glioblastoma xenograft - Control 34.7648373
GSM967855U87-EV human glioblastoma xenograft - Control 43.9190765
GSM967856U87-EV human glioblastoma xenograft - Control 54.2435869
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6614273
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9337375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2405169
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2660369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2933669
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3389270
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7395263
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3607670
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3455670